Sector Expert: David Nierengarten


Image: David Nierengarten

David Nierengarten is an analyst covering stocks in the biotechnology sector. His prior sellside research experience at Robert W. Baird & Co. covered biotechnology companies of all market capitalizations, with a focus on oncology and rare diseases. Nierengarten's prior early-stage venture capital investing experience helps him evaluate developmental-stage biotechnology companies that comprise his current major coverage focus. His experience on the other side of that equation, in a clinical-stage, venture-backed biotechnology company, provides him with additional insights into corporate operations. He received his bachelor's degree in biochemistry from the University of Wisconsin-Madison and his Ph.D. in molecular and cell biology from the University of California Berkeley.

Recent Interviews

Novel Technology Platforms with Dramatic Growth Potential: Wedbush's David Nierengarten (8/26/15)

In the past five years, development of new therapies has aimed for true disease modification and actual cures. Many novel ideas are now in the clinic, and have opened up fresh opportunities for dramatic industry growth, especially in the gene and cellular therapy realm. In this interview with The Life Sciences Report, David Nierengarten of Wedbush Securities brings a handful of select names to investors' attention, including a couple of companies with technologies that could revolutionize medicine.

Wedbush Securities' David Nierengarten on Genetic Cures for Disease: Impossible Dream Come True? (12/11/14)

Clinicians like to speak in terms of "managing" disease. That term of art is an admission that, in most cases, they can't cure the serious problems confronting patients. In this interview with The Life Sciences Report, David Nierengarten of Wedbush Securities explores gene therapies that actually correct an inborn mutation in human DNA, creating permanent change, actual cures and better lives for patients. It sounds beyond the reach of medicine. . .and therein lies the opportunity: Investors in gene therapy companies may capture serious returns on risk capital when the cure is attained.

Recent Quotes

"SNSS does have a path forward in Europe, where it has a shot at approval for Qinprezo."

The Life Sciences Report Interview with David Nierengarten (8/26/15)
more >

"We are expecting approval in the European Union of SNSS' vosaroxin."

— David Nierengarten, Wedbush (7/30/15)
more >

"SNSS says filing the MAA in the EU is now its top priority."

— David Nierengarten, Wedbush (7/23/15)
more >

"Data show that SNSS' vosaroxin has a potential treatment role in AML."

— David Nierengarten, Wedbush (6/12/15)
more >

"SNSS ended Q1/15 with $40M in cash and cash equivalents."

— David Nierengarten, Wedbush (5/5/15)
more >

"SNSS will present further analyses of the vosaroxin data in June."

— David Nierengarten, Wedbush (3/16/15)
more >

Due to permission requirements, not all quotes are shown.